Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant giredestrant versus physician's choice endocrine monotherapy in ER-positive, HER2-negative early breast cancer
2021-000129-28Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of giredestrant in breast cancer and Estrogen receptor-positive HER2-negative breast cancer (ER+/HER2-) (2 arms), sponsored by Roche. Primary endpoint: Invasive disease-free survival. Started Jun 2021; status: active.
02
Drugs
giredestrant
03
Conditions
breast cancerEstrogen receptor-positive HER2-negative breast cancer (ER+/HER2-)
Beyond the preview
Go deeper on 2021-000129-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000129-28.